CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience. Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print]. Multinucleated giant myeloma cells after failure of daratumumab therapy. Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print]. Defining a set of standardised outcome measures for newly diagnosed patients…
Celgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…
Results from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…
The National Institute of Health and Care Excellence (NICE) has approved the use of daratumumab (Darzalex®) monotherapy as a treatment for relapsed and refractory myeloma patients. This treatment will be made available through the Cancer Drugs Fund (CDF) to patients in England and Wales who have received 3 prior treatments, including a proteasome inhibitor and…
Results from the Phase III TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial have recently been reported at the American Society of Haematology 2017 conference. This study assessed the benefit of levofloxacin antibiotic prophylaxis and its effect on healthcare associated infections in newly diagnosed myeloma patients. The results show that levofloxacin prophylaxis had a…
A meta-analysis conducted by researchers at the University of Pennsylvania has shown that treatment with carfilzomib (Kyprolis®) is associated with a higher incidence of cardiovascular events in myeloma patients. The study found that 18.1% of myeloma patients receiving carfilzomib experienced cardiovascular events, including hypertension, cardiac arrest, cardiac failure and arrhythmias, compared to only 3.8% of…
This paper, written by a panel of experts from the International Myeloma Working Group (IMWG), reviews the available data on second primary malignancies in myeloma, and provides recommendations for treatment and management.
This paper, produced by an expert panel of the International Myeloma Working Group (IMWG) reviews the assessment of disease response and endpoints for clinical trials, and provides updated response categories of minimal residual disease negativity.
This paper, produced by the International Myeloma Working Group (IMWG), provides an updated definition of high-risk myeloma based on cytogenetics and provides recommendations for the optimum treatment for this group of myeloma patients.
This paper, written by the International Myeloma Working Group (IMWG), reviews the current evidence, and provides recommendations for the management of patients with relapsed myeloma.